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Objective: Pulmonary arteriovenous malformations may cause progressive cyanosis
after cavopulmonary anastomosis and may develop as a result of abnormal angio-
genesis. We used immunohistochemistry to determine whether angiogenic proteins
are increased in the lungs of children after cavopulmonary anastomosis.
Methods: Lung specimens were obtained from 13 children after cavopulmonary
anastomosis and from 6 control subjects. Specimens were stained with antibodies
against vascular endothelial growth factor and its receptor (flk-1/KDR), basic
fibroblast growth factor, α-smooth muscle actin, CD31, collagen IV, fibronectin,
and proliferating cell nuclear antigen. Staining was graded on a scale of 0 to 3.
Vessels positive for proliferating cell nuclear antigen were counted in 10 fields per
specimen, and the results were averaged.
Results: After cavopulmonary anastomosis, patients demonstrated increased stain-
ing for vascular endothelial growth factor (P = .03) and its receptor (P = .03) and
decreased staining for CD31 (P = .004). Proliferating cell nuclear antigen staining
in patients was equivalent to that for control subjects (P = .9).
Conclusions: Lung biopsy specimens from children after cavopulmonary anasto-
mosis demonstrate increased expression of vascular endothelial growth factor and
its receptor. These data confirm earlier findings that blood vessels forming after
cavopulmonary anastomosis may have reduced intercellular junctions (decreased
CD31 staining). Despite the increased numbers of pulmonary vessels that are pres-
ent in these patients, these vessels are not highly proliferative (proliferating cell
nuclear antigen staining equivalent to that of control subjects). These results suggest
that vascular endothelial growth factor may be a mediator of angiogenesis in the
lungs of children after cavopulmonary anastomosis; however, other factors, such as
vascular dilation and remodeling, may also be important.
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Pulmonary arteriovenous malformations(PAVMs) are a frequent cause of progressivecyanosis in children after cavopulmonaryanastomosis. The development of PAVMsmay represent a form of abnormal angiogene-sis that is under hepatic control.1 We have pre-
viously reported a detailed histologic description of PAVMs
in 2 children after cavopulmonary anastomosis.2 Peripheral
lung biopsy specimens from these children demonstrated
numerous dilated vessels, suggesting that PAVMs are angio-
genically active lesions. In addition, we have shown that
children demonstrate increased numbers of pulmonary
blood vessels early after cavopulmonary anastomosis, even
without clinical evidence of PAVMs.3 This suggests that
after cavopulmonary anastomosis, there is a constant angio-
genic stimulus that may ultimately lead to the development
of clinically apparent PAVMs.
Angiogenesis involves the interaction of many proteins,
such as growth factors (vascular endothelial growth factor
[VEGF] and basic fibroblast growth factor [bFGF]), extra-
cellular matrix proteins, and tissue proteases. We assessed
the expression of several proteins known to be important in
angiogenesis in lung biopsy specimens from children after
cavopulmonary anastomosis by using immunohistochem-
istry to determine whether these proteins are upregulated.
Methods
Patients
After obtaining consent, we obtained lung biopsy specimens at the
time of the Fontan procedure from 13 children who had previous-
ly undergone a cavopulmonary anastomosis. Four of these children
had documented PAVMs on angiography performed before the
Fontan procedure. Lung biopsy specimens were obtained from the
lingula or the right middle lobe through the sternotomy incision
with full lung inflation and immediately fixed. Control lung spec-
imens from 4 children without congenital heart disease or signifi-
cant lung disease were obtained from archived specimens as
described,3 and 2 control specimens were obtained as lung biopsy
specimens from children with acyanotic congenital heart disease at
the time of operative repair (Ross procedure; aortic coarctation
repair). Two archived control specimens were lung biopsy speci-
mens from a child with an acute viral illness and a child with sys-
temic lupus erythematosis. The other 2 archived control specimens
were autopsy specimens from a child who died of acute viral
myocarditis and a child who died of rabies encephalitis. All
archived control specimens were obtained from patients who had a
duration of illness of less than 1 week before the time the speci-
mens were obtained. The study was approved by the Institutional
Review Board of Children’s Hospital and Regional Medical Center
(Seattle, Wash).
Histology and Immunohistochemistry
All surgical and autopsy specimens were fixed in formalin, embed-
ded in paraffin, and processed as described.2 In brief, 5-µm sec-
tions were deparaffinized in xylene and rehydrated in graded alco-
hols. Primary antibodies were diluted in 1% bovine serum albumin
(BSA) in phosphate-buffered saline solution (PBS) and applied to
sections. Antibodies used included a monoclonal antibody against
VEGF (Santa Cruz Biotechnology, Santa Cruz, Calif) diluted
1:200, a polyclonal antibody against VEGF receptor (flk-1/KDR;
kindly provided by Dr Rolf Brekken, Division of Vascular Biology,
Hope Heart Institute, Seattle, Wash) diluted 1:10, a monoclonal
antibody against bFGF (Oncogene, Cambridge, Mass) diluted
1:250, a monoclonal antibody against fibronectin (Chemicon,
Temecula, Calif) diluted 1:250, a monoclonal antibody against α-
smooth muscle actin diluted 1:250, a monoclonal antibody against
CD31 diluted 1:50, a monoclonal antibody against collagen IV
diluted 1:300, and a monoclonal antibody against proliferating cell
nuclear antigen (PCNA) diluted 1:50 (all from DAKO Cor-
poration, Carpinteria, Calif). Before the addition of primary anti-
body against bFGF, flk-1/KDR, fibronectin, collagen IV, and
CD31, sections were predigested with 0.01% protease or trypsin
for 10 minutes. Biotinylated horse anti-mouse or goat anti-rabbit
secondary antibody (Vector Laboratories, Burlingame, Calif) dilut-
ed 1:500 in 1% BSA/PBS were then applied, and sections were
incubated for 30 minutes. Avidin-biotin enzyme complex (Vector
Laboratories) was added, and slides were incubated for 30 minutes
at room temperature. The sections were developed with
diaminobenzidine tetrahydrochloride (Sigma Laboratories, St
Louis, Mo) and counterstained in methyl green. Appropriate posi-
tive controls were used, and negative controls consisting of sec-
tions incubated in 1% BSA/PBS in place of the primary antibody
were examined to ensure that staining was specific.
Specimen Grading and Statistical Analysis
All sections were graded by 3 investigators using a scale of 0 to 3.
A score of 0 qualified as no staining, 1 as minimal staining, 2 as
moderate staining, and 3 as intense staining. Staining scores were
then compared between patients who had undergone cavopul-
monary anastomosis and control subjects with the Fisher exact
test. For sections stained with PCNA, positively stained vessels
were counted in 10 high-power fields (HPFs; 250×) by 2 investi-
gators, and these results were averaged for each patient and control
subject. The average of the mean number of vessels per HPF from
each individual was then determined for the following groups:
asymptomatic patients after cavopulmonary anastomosis; patients
with clinically evident PAVMs after cavopulmonary anastomosis;
and control subjects. The averages of the means for all patients
after cavopulmonary anastomosis were then compared with those
of control subjects by the Student t test. The averages of the means
for each of these 3 groups were also compared by 1-way analysis
of variance. All statistical analyses were performed with SAS soft-
ware version 6.12 (SAS Institute, Cary, NC).
Results
The demographics for the 13 children who had undergone
cavopulmonary anastomosis are summarized in Table 1. The
median age for patients after cavopulmonary anastomosis
was 4.1 years (range, 1.8-12.0 years), and the median age
was 4.6 years (range, 0.8-15.0 years) for control subjects.
Four of the 13 patients had documented PAVMs on angiog-
raphy performed before the Fontan procedure; 3 of these
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patients were significantly hypoxemic as well. The other 9
patients had no angiographic or clinical evidence of PAVMs
after cavopulmonary anastomosis. The control specimens
showed only minor abnormalities on microscopic examina-
tion: 3 specimens were completely normal; 2 showed mild
focal inflammation; and 1 showed mild focal fibrosis. Eight
of the patients who underwent cavopulmonary anastomosis
and 4 of the control subjects have had their pulmonary
microvessel densities compared and reported, as determined
by von Willebrand factor staining.3
Figure 1 demonstrates the staining grade for VEGF,
VEGF receptor (flk-1/KDR), CD31, bFGF, actin, collagen
IV, and fibronectin for asymptomatic patients after cavopul-
monary anastomosis, for patients with clinical evidence of
PAVMs after cavopulmonary anastomosis, and for control
subjects. After cavopulmonary anastomosis, children
demonstrated increased staining for VEGF (P = .03) and its
receptor (P = .03). VEGF staining was cytoplasmic and
localized mainly to vascular endothelium and alveolar
epithelial cells. VEGF receptor staining was localized to the
vascular endothelium. After cavopulmonary anastomosis,
patients demonstrated decreased CD31 staining of the vas-
cular endothelium compared with that seen in control sub-
jects (P = .004). The lungs of control patients had continu-
ous, dark CD31 staining of most vessels, whereas those of
patients after cavopulmonary anastomosis demonstrated
patchy or absent staining of most vessels. There was no sig-
nificant difference in staining intensity for bFGF, actin, col-
lagen IV, and fibronectin between patients and control sub-
jects. Figure 2 demonstrates representative sections from a
patient after cavopulmonary anastomosis and a control
patient stained for VEGF, flk-1/KDR, and CD31.
Averages of the means of PCNA-positive cells per 10
HPFs were not significantly different for patients after
cavopulmonary anastomosis (21.7 ± 9.8) and control sub-
jects (24.7 ± 7.5, P = .9). There were also no significant dif-
ferences in PCNA staining between asymptomatic patients
after cavopulmonary anastomosis (20 ± 8.3), patients with
clinical evidence of PAVMs after cavopulmonary anastomo-
sis (25.5 ± 9.4), and control subjects (24.7 ± 7.5, P = .6).
Discussion
PAVMs may develop in the lungs of children after palliative
cardiac operations, most often after a cavopulmonary anas-
tomosis. These abnormal vascular lesions result in right-to-
left shunting, which causes significant morbidity because of
the development of progressive cyanosis. PAVMs develop-
ing after cavopulmonary anastomosis may represent a form
of abnormal angiogenesis, although little is known about the
mechanism of their formation or the specific factors
involved. We have previously reported a detailed histologic
analysis of these lesions in 2 of the patients included in the
present study.2 Lung biopsy specimens from these patients
with documented PAVMs after cavopulmonary anastomosis
demonstrated large numbers of clustered microvessels
(chains) and large, dilated, thin-walled vessels (lakes).
These vessels demonstrated discontinuity of the basement
membrane and endothelium by means of electron
microscopy. Although providing the first detailed micro-
scopic analysis of these lesions, this initial study did not
provide much evidence as to their likely cause.
The present study provides the first report of the possi-
ble involvement of specific angiogenic factors in the cause
of PAVMs that develop after cavopulmonary anastomosis.
VEGF and bFGF are 2 potent mediators of angiogenesis
that have been shown to be increased in tumors from
numerous tissue types.4-6 In addition, VEGF and bFGF
have been shown to be upregulated in nonneoplastic con-
TABLE 1. Demographics of patients after cavopulmonary anastomosis
Age (y) Oxygen saturation (%) Diagnosis Time since Glenn shunt (y) Clinically evident PAVM?
Patient 1 3.0 83 Heterotaxy 2.2 Yes
Patient 2 12.0 65 Heterotaxy 7.0 Yes
Patient 3 7.9 71 TGA, DILV, CoA, AS 6.6 Yes
Patient 4 1.9 85 Tricuspid atresia 1.3 No
Patient 5 2.9 84 Pulmonary atresia 1.7 No
Patient 6 3.4 84 Pulmonary atresia 1.8 No
Patient 7 3.9 80 Tricuspid atresia 3.5 No
Patient 8 1.8 85 HLHS 1.4 No
Patient 9 2.6 85 HLHS 2.0 No
Patient 10 2.8 88 TGA, DILV, PS 2.1 No
Patient 11 3.3 84 PA/IVS 2.2 No
Patient 12 3.3 85 Tricuspid atresia 2.8 No
Patient 13 4 88 Heterotaxy 2.7 Yes
TGA, Transposition of the great arteries; DILV, double-inlet left ventricle; CoA, aortic coarctation; AS, aortic stenosis; HLHS, hypoplastic left heart syn-
drome; PS, pulmonic stenosis; PA/IVS, pulmonary atresia/intact ventricular septum.
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ditions associated with angiogenesis, such as proliferative
retinopathy and psoriasis.7 In the present study, after
cavopulmonary anastomosis, patients demonstrated
increased staining for VEGF but not bFGF. This pattern
was fairly consistent, with all but one patient demonstrat-
ing increased VEGF expression after cavopulmonary anas-
tomosis. We also demonstrated increased staining for the
VEGF receptor flk-1/KDR in our patients. The VEGF
receptor flk-1/KDR is a tyrosine kinase receptor that has
been linked to the mitogenic response of endothelial cells
to VEGF.8 This receptor is downregulated in normal dif-
ferentiated adult endothelium, but its expression is
increased in angiogenic states.9 The finding of increased
flk-1/KDR expression in the lungs of children who have
undergone cavopulmonary anastomosis also supports an
increased angiogenic state in these patients, which may be
mediated by VEGF.
The pattern of development of PAVMs in children after
cavopulmonary anastomosis suggests that synthetic or meta-
bolic functions of the liver may play a causative role. PAVMs
form in the ipsilateral lung after a classic Glenn shunt10 and
bilaterally after a bidirectional Glenn shunt or Kawashima
procedure.11 In each of these cases, PAVMs develop in the
portion of the pulmonary circulation that is devoid of hepatic
venous effluent. Performing a Fontan procedure reconstitutes
hepatic venous drainage to the lungs, which results in regres-
sion of PAVMs.12 Further evidence for the role of the liver in
this phenomenon comes from the observation that a similar
clinical picture is seen in some patients with liver failure who
have progressive cyanosis from intrapulmonary shunting.
This phenomenon, termed the hepatopulmonary syndrome,
closely resembles the angiographic and histologic picture of
PAVMs occurring after cavopulmonary anastomosis and
resolves after liver transplantation.13,14
The patterns of development of PAVMs seen in these
various conditions combined with the data presented in the
present study now allow us to develop a hypothesis regard-
ing the cause of PAVMs that develop after cavopulmonary
anastomosis. An inhibitor of angiogenesis that is normally
present in hepatic venous effluent may be absent in the
pulmonary arterial circulation after cavopulmonary anasto-
mosis. Alternatively, a proangiogenic substance that is nor-
mally degraded by the liver may now be present in higher con-
centrations in the pulmonary circulation after cavopulmonary
anastomosis. The result of either of these derangements would
be the activation of VEGF-mediated angiogenesis in the lungs
of these children. We have partially purified a novel inhibitor
of angiogenesis from hepatocyte-conditioned media that
would support the presence of a hepatic derived inhibitor of
angiogenesis that normally holds pulmonary vascular prolifer-
ation in check.1 The present study suggests that upregulation
of local expression of both VEGF and VEGF receptor is
increased as a result of these mechanisms. As further evidence
for this hypothesis, we have recently shown that there appears
to be a constant angiogenic stimulus in the lungs of children
after cavopulmonary anastomosis by demonstrating that a
marker of angiogenesis (microvessel density) is increased in
children early after cavopulmonary anastomosis, even in the
absence of clinically evident PAVMs.3
In the present study we also sought to confirm previous
preliminary immunohistochemical analysis of lung biopsy
specimens from children who have undergone cavopul-
monary anastomosis. The pattern of CD31 staining that we
observed here is the same as that found in our earlier study.2
CD31 is an adhesion molecule that is present at endothelial
intercellular junctions.15 We have consistently found
decreased staining for this marker after cavopulmonary
anastomosis compared with that seen in control subjects.
This correlates with the finding of basement membrane and
endothelial discontinuity on electron microscopy in children
after PAVM.2 Increased numbers of vessels with diminished
intercellular junctions might contribute to the clinical phe-
Figure 1. Staining grade for VEGF, VEGF receptor (flk-1/KDR), CD31, bFGF, α-smooth muscle actin, collagen IV, and
fibronectin. Filled squares represent patients with clinically evident PAVMs and filled circles represent patients
without clinically evident PAVMs after cavopulmonary anastomosis. Open circles represent control patients.
Staining was graded on a scale of 0 (no staining) to 3 (intense staining).
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nomenon of capillary leak and pleural effusions that arise as
a result of elevated central venous pressure after the Fontan
procedure. VEGF is also known to increase vascular perme-
ability16 and may be linked to the decrease in CD31 expres-
sion seen in our patients.
The present study also confirms our earlier observations
that despite increased numbers of vessels in these patients,
these vessels do not show evidence of intense proliferation,
as determined with PCNA staining. PCNA is a nuclear pro-
tein that is associated with rapidly proliferating cells.17
Most of the specimens in the present study did not demon-
strate vessels with increased PCNA staining. One explana-
tion for this finding is that the phase of intense cellular pro-
liferation may have occurred earlier during the development
of PAVMs because PCNA is known to be expressed early in
proliferating tissue and only for a limited time.17
There are limitations to this study. Importantly, the pres-
ent study does not definitively rule out alternative causes
for PAVM development. For example, there is evidence that
dilatation of existing embryonal vascular channels in the
lungs of these children may also contribute to the develop-
ment of PAVM after cavopulmonary anastomosis.18 The
presence of mechanisms related to vascular remodeling and
dilatation in this condition may help to explain the minimal
PCNA staining that we have observed. Another potential
causative factor for which the present study fails to control
is the influence of hypoxia on the expression of angiogenic
proteins in the lungs of these children. Hypoxia is a potent
stimulus of angiogenesis and upregulates angiogenic fac-
tors, such as VEGF.19 Interestingly, we have shown
increased VEGF levels, determined by means of enzyme-
linked immunosorbent assay, in the serum of children with
cyanotic congenital heart disease compared with that seen
in control subjects.20 Although these results were found in
the serum of cyanotic patients, it is unknown whether
chronic hypoxia may result in elevations of VEGF or its
receptor in the tissues.
We believe that the absence of a hepatic derived inhibitor
of angiogenesis in the pulmonary circulation will prove to
be a major factor leading to PAVM formation; however, this
process is complex and undoubtedly involves many compo-
nents. mRNA levels for VEGF and VEGF receptor should
be determined for lung biopsy specimens from these chil-
dren to confirm the findings from the present study on the
basis of immunohistochemical changes. In addition, protein
expression and mRNA levels of mediators of vascular
remodeling and dilatation will need to be examined. 
Finally, the effect of chronic cyanosis on the tissue
expression of angiogenic proteins could be assessed in the
future by including analyses of lung biopsy specimens from
hypoxic patients who have not undergone a cavopulmonary
anastomosis. The importance of the development of an ani-
Figure 2. Representative staining for VEGF (A, D), VEGF receptor (flk-1/KDR) (B, E), and CD31 (C, F) in a patient after
cavopulmonary anastomosis (A-C) and a control subject (D-F). (Arrowheads demonstrate  blood  vessels.)
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mal model for the ultimate understanding of this condition
cannot be overstated and remains an ongoing objective of
our laboratory investigation.
Surgery
VEGF and its receptor appear to be increased in lung
biopsy specimens from children after cavopulmonary
anastomosis; however, these vessels do not appear to be
highly proliferative. This is the first reported example of
increased expression of any angiogenic factor in patients
after cavopulmonary anastomosis. However, PAVM
development that occurs in these children is undoubtedly
caused by multiple processes that may include angiogen-
esis, recruitment of existing embryonal channels, and vas-
cular remodeling.
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